Tag: cell and gene therapy cdmo market growth

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

#What Is the Current and Projected Market Size of the Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market Through 2034?#_x000D_

The market Size of the contract development and manufacturing organization (cdmo) for cell and gene therapy has seen robust growth in recent years. The market is projected to burgeon from $5.41 billion in 2024 to $6.92 billion in 2025, with a compound annual growth rate (CAGR) of 27.9%. The historical growth of the market can be credited to factors such as advanced technology, supportive regulatory policies, increased investment activities, high incidence of genetic diseases, and a rise in strategic collaborations._x000D_

_x000D_

Expectations suggest that the market size for the contract development and manufacturing organization (cdmo) connected to cell and gene therapy will witness a significant surge in the coming years. The projections show an upward climb to$17.57 billion in 2029 with a compound annual growth rate (CAGR) of 26.2%. The growth predicted in the forecast period can be credited to factors such as broader therapeutic applications, a changing regulatory landscape, swelling investments, technology advancements, and global cooperation. The key market trends in the given forecast period encompass a higher requirement for personalized treatments, growth in automation and digitization, manufacturing capacity expansion, the emergence of innovative delivery systems, and an increased emphasis on sustainability and the environmental footprint._x000D_

_x000D_

#Download a free sample to assess the report’s scope and structure:#_x000D_

https://www.thebusinessresearchcompany.com/sample.aspx?id=15753&type=smp_x000D_

_x000D_

#What Are the Major Market Drivers Behind the Rising Adoption of Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market?#_x000D_

The rise in cancer incidents is anticipated to fuel the expansion of the cell and gene therapy contract development and manufacturing organization (CDMO) market. Cancer encompasses a variety of diseases marked by unchecked growth and the proliferation of abnormal cells. Aging populations, lifestyle transformations, environmental exposure and enhanced detection techniques all contribute to the increase in cancer cases. The role of a CDMO in the cell and gene therapy space is to curtail the prevalence of cancer by drafting and manufacturing innovative, focused treatments that improve effectiveness and patient results. For instance, Macmillan Cancer Support, a UK charity, estimated in October 2022, that the number of people in the UK living with cancer is expected to rise from 3 million in 2022 to 3.5 million by 2025, reaching 4 million by 2030 and 5.3 million by 2040. This rise in cancer cases is therefore a key driver behind the growth of the cell and gene therapy contract development and manufacturing organization (CDMO) market._x000D_

_x000D_

#Which Key Market Segments Comprise the Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market and Drive Its Revenue Growth?#_x000D_

The cell and gene therapy contract development and manufacturing organization (cdmo)market covered in this report is segmented – _x000D_

_x000D_

1) By Product Type: Gene Therapy; Gene-Modified Cell Therapy; Cell Therapy_x000D_

2) By Phase: Phase 1; Phase 2; Phase 3; Phase 4_x000D_

3) By Indication: Oncology; Infectious Diseases; Neurological Disorders; Rare Diseases; Other Indications_x000D_

_x000D_

Subsegments:_x000D_

1) By Gene Therapy: Viral Vector-Based Gene Therapy; Non-Viral Gene Therapy; Plasmid DNA-Based Gene Therapy_x000D_

2) By Gene-Modified Cell Therapy: CAR-T Cell Therapy; TCR-T Cell Therapy; NK Cell Therapy_x000D_

3) By Cell Therapy: Stem Cell Therapy; Progenitor Cell Therapy; Immune Cell Therapy_x000D_

_x000D_

#Request customized data on this market:#_x000D_

https://www.thebusinessresearchcompany.com/customise?id=15753&type=smp_x000D_

_x000D_

#Which Areas Are Leading Regions in the Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market Expansion Across the Globe?#_x000D_

North America was the largest region in the cell and gene therapy contract development and manufacturing organization (CDMO) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cell and gene therapy contract development and manufacturing organization (CDMO) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa._x000D_

_x000D_

#What Are the Strategic Trends Steering theCell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market Direction?#_x000D_

Leading firms in the cell and gene therapy contract development and manufacturing organization (CDMO) market are broadening their scope of services with sophisticated solutions like the PluriMatrix technology. This is primarily aimed at improving the scalability, effectiveness, and caliber of manufacturing cell-based products. PluriMatrix technology is an exclusive system designed for large-capacity output of cell-focused products. This state-of-the-art technology enables 3D growth of cells on a large scale while ensuring superior yield and uniform quality through a completely automated, controlled, and verified procedure. As an example, in January 2024, Pluri, an Israeli biotech firm, rolled out PluriCDMO, a fresh business segment that provides cell therapy manufacturing services as a CDMO. This new unit includes a robust 47,000-square-foot good manufacturing practice (GMP) cell therapy manufacturing facility. The new division of Pluri provides comprehensive services from the initial preclinical phase to late-stage clinical trials and commercialization. This includes process and analytical development, scaling up, validation, logistics, automation, and regulatory-approved equivalence studies, as mentioned in a corporate press release. Furthermore, the leading-edge PluriMatrix technology of the company is utilized to provide advanced cell therapy manufacturing services._x000D_

_x000D_

#View the full report here:#_x000D_

https://www.thebusinessresearchcompany.com/report/cell-and-gene-therapy-contract-development-and-manufacturing-organization-cdmo-global-market-report_x000D_

_x000D_

#How Is the Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market Conceptually Defined?#_x000D_

A cell and gene therapy contract development and manufacturing organization (CDMO) is a specialized company that provides services to support the development, manufacturing, and commercialization of cell-based and gene therapy products. These organizations offer services tailored to the unique needs of companies developing advanced therapies, including biopharmaceutical companies, academic institutions, and government agencies. Cell and gene therapy CDMOs play a critical role in accelerating the development and commercialization of advanced therapy products by offering specialized expertise, infrastructure, and services to support their clients’ needs from early-stage development through commercialization._x000D_

_x000D_

#Purchase the full report and get a swift delivery:#_x000D_

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15753_x000D_

_x000D_

#About The Business Research Company:#_x000D_

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game._x000D_

_x000D_

#Get in touch with us:#_x000D_

The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_

Americas +1 310-496-7795_x000D_

Europe +44 7882 955267_x000D_

Asia & Others +44 7882 955267 & +91 8897263534_x000D_

Email us at info@tbrc.info_x000D_

_x000D_

#Follow us on:#_x000D_

_x000D_

LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Are the Projected Market Size and Growth Rates for the Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market From 2025 To 2029?

The market size of contract development and manufacturing organizations (CDMO) for cell and gene therapy has witnessed significant expansion in the past few years. The market is forecasted to escalate from $5.41 billion in 2024 to $6.94 billion in 2025, indicating a compound annual growth rate (CAGR) of 28.2%. This surge during the historical period is largely owed to advancements in technology, supportive regulatory environment, amplified funding, a high incidence of genetic disorders, and the growth in strategic collaborations.

What Is the Projected Market Size of the Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market?

The market for contract development and manufacturing organizations (CDMO) in the cell and gene therapy sector is projected to undergo significant expansion in the coming years. Its value is forecasted to reach $18.54 billion by 2029, with a compound annual growth rate (CAGR) of 27.8%. Contributing factors to this projected growth during the forecast period include a broadening of therapeutic applications, changing regulatory landscapes, boosting investments, technological advancements, and global partnerships. The forecast period is also likely to see trends such as a growing demand for personalized treatment options, an increase in automation and digitalization, manufacturing capacity expansions, the rise of innovative delivery systems, and an enhanced focus on environmental sustainability.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15753&type=smp

Who are the Major Competitors in the Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market Outlook?

Major companies operating in the cell and gene therapy contract development and manufacturing organization (CDMO) market are Pfizer Inc., Merck & Co. Inc., Thermo Fisher Scientific Inc., Novartis AG, FUJIFILM Diosynth Biotechnologies, AGC Biologics, Ajinomoto Co Inc., Lonza Group, Catalent Inc., Charles River Laboratories International Inc., Sartorius Stedim Biotech, Samsung Biologics Co Ltd., WuXi Biologics, Recipharm AB, Almac Group Ltd., KBI Biopharma, Rentschler Biopharma, Bio Elpida, Oxford BioMedica Plc, Avid Bioservices Inc., Cell and Gene Therapy Catapult, VGXI Inc., Genezen Laboratories Inc., Pluri Inc., OmniaBio Inc.

What Is Fueling Growth in the Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market?

The escalating incidence of cancer is expected to drive the expansion of the cell and gene therapy contract development and manufacturing organization (CDMO) market in the future. Cancer, a group of diseases marked by the uncontrolled proliferation and dispersion of abnormal cells in the body, has been increasingly prevalent because of aging demographics, lifestyle modifications, environmental triggers, and better diagnostic methods. Cell and gene therapy contract development and manufacturing organization (CDMO) plays a crucial role in decreasing the incidence of cancer by creating and producing innovative, targeted therapies that improve efficacy and patient outcomes. For instance, in October 2022, Macmillan Cancer Support, a UK-based charity, projected that the population of individuals living with cancer in the UK is set to rise from 3 million in 2022 to 3.5 million by 2025, 4 million by 2030, and 5.3 million by 2040. Hence, the escalating incidence of cancer fuels the expansion of the cell and gene therapy contract development and manufacturing organization (CDMO) market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=15753&type=smp

Which Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market Segments Are Growing the Fastest?

The cell and gene therapy contract development and manufacturing organization (CDMO) market covered in this report is segmented –

1) By Product Type: Gene Therapy, Gene-Modified Cell Therapy, Cell Therapy

2) By Phase: Phase 1, Phase 2, Phase 3, Phase 4

3) By Indication: Oncology, Infectious Diseases, Neurological Disorders, Rare Diseases, Other Indications

Subsegments:

1) By Gene Therapy: Viral Vector-Based Gene Therapy, Non-Viral Gene Therapy, Plasmid DNA-Based Gene Therapy

2) By Gene-Modified Cell Therapy: CAR-T Cell Therapy, TCR-T Cell Therapy, NK Cell Therapy

3) By Cell Therapy: Stem Cell Therapy, Progenitor Cell Therapy, Immune Cell Therapy

Which Industry Trends Are Shaping the Future of the Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market?

Leading corporations in the cell and gene therapy contract development and manufacturing organization (CDMO) market are making concerted efforts to broaden their offerings with technological advancements like PluriMatrix. This is with the aim of boosting scalability, productivity, and the standard of cell-based goods production. The PluriMatrix system is specifically designed for high-volume production of cell-based items. Ensuring high yield and uniform quality, this technology enhances the 3D expansion of cells on a commercial scale through a validated, automated, and fully controlled process. For example, in January 2024, Pluri, a biotech company based in Israel, introduced PluriCDMO, a fresh business unit offering cell therapy manufacturing services under the CDMO model. The new unit encompasses a 47,000-square-foot facility for good manufacturing practice (GMP) cell therapy production. Pluri’s new division delivers comprehensive services, from early preclinical stages to late-stage clinical trials and eventual commercialization. This encompasses process and analytical development, scale-up, validation, logistics, automation, and regulatory-approved comparability studies, as elucidated in an official company announcement. With its advanced PluriMatrix technology, the company is able to provide sophisticated cell therapy manufacturing services.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/cell-and-gene-therapy-contract-development-and-manufacturing-organization-cdmo-global-market-report

Which Countries Are Leading the Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market?

North America was the largest region in the cell and gene therapy contract development and manufacturing organization (CDMO) market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cell and gene therapy contract development and manufacturing organization (CDMO) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15753

This Report Delivers Insight On:

1. How big is the cell and gene therapy contract development and manufacturing organization (cdmo) market, and how is it changing globally?

2. Who are the major companies in the cell and gene therapy contract development and manufacturing organization (cdmo) market, and how are they performing?

3. What are the key opportunities and risks in the cell and gene therapy contract development and manufacturing organization (cdmo) market right now?

4. Which products or customer segments are growing the most in the cell and gene therapy contract development and manufacturing organization (cdmo) market?

5. What factors are helping or slowing down the growth of the cell and gene therapy contract development and manufacturing organization (cdmo) market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Are the Projected Market Size and Growth Rates for the Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market From 2025 To 2029?

The market size of contract development and manufacturing organizations (CDMO) for cell and gene therapy has witnessed significant expansion in the past few years. The market is forecasted to escalate from $5.41 billion in 2024 to $6.94 billion in 2025, indicating a compound annual growth rate (CAGR) of 28.2%. This surge during the historical period is largely owed to advancements in technology, supportive regulatory environment, amplified funding, a high incidence of genetic disorders, and the growth in strategic collaborations.

What Is the Projected Market Size of the Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market?

The market for contract development and manufacturing organizations (CDMO) in the cell and gene therapy sector is projected to undergo significant expansion in the coming years. Its value is forecasted to reach $18.54 billion by 2029, with a compound annual growth rate (CAGR) of 27.8%. Contributing factors to this projected growth during the forecast period include a broadening of therapeutic applications, changing regulatory landscapes, boosting investments, technological advancements, and global partnerships. The forecast period is also likely to see trends such as a growing demand for personalized treatment options, an increase in automation and digitalization, manufacturing capacity expansions, the rise of innovative delivery systems, and an enhanced focus on environmental sustainability.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15753&type=smp

Who are the Major Competitors in the Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market Outlook?

Major companies operating in the cell and gene therapy contract development and manufacturing organization (CDMO) market are Pfizer Inc., Merck & Co. Inc., Thermo Fisher Scientific Inc., Novartis AG, FUJIFILM Diosynth Biotechnologies, AGC Biologics, Ajinomoto Co Inc., Lonza Group, Catalent Inc., Charles River Laboratories International Inc., Sartorius Stedim Biotech, Samsung Biologics Co Ltd., WuXi Biologics, Recipharm AB, Almac Group Ltd., KBI Biopharma, Rentschler Biopharma, Bio Elpida, Oxford BioMedica Plc, Avid Bioservices Inc., Cell and Gene Therapy Catapult, VGXI Inc., Genezen Laboratories Inc., Pluri Inc., OmniaBio Inc.

What Is Fueling Growth in the Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market?

The escalating incidence of cancer is expected to drive the expansion of the cell and gene therapy contract development and manufacturing organization (CDMO) market in the future. Cancer, a group of diseases marked by the uncontrolled proliferation and dispersion of abnormal cells in the body, has been increasingly prevalent because of aging demographics, lifestyle modifications, environmental triggers, and better diagnostic methods. Cell and gene therapy contract development and manufacturing organization (CDMO) plays a crucial role in decreasing the incidence of cancer by creating and producing innovative, targeted therapies that improve efficacy and patient outcomes. For instance, in October 2022, Macmillan Cancer Support, a UK-based charity, projected that the population of individuals living with cancer in the UK is set to rise from 3 million in 2022 to 3.5 million by 2025, 4 million by 2030, and 5.3 million by 2040. Hence, the escalating incidence of cancer fuels the expansion of the cell and gene therapy contract development and manufacturing organization (CDMO) market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=15753&type=smp

Which Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market Segments Are Growing the Fastest?

The cell and gene therapy contract development and manufacturing organization (CDMO) market covered in this report is segmented –

1) By Product Type: Gene Therapy, Gene-Modified Cell Therapy, Cell Therapy

2) By Phase: Phase 1, Phase 2, Phase 3, Phase 4

3) By Indication: Oncology, Infectious Diseases, Neurological Disorders, Rare Diseases, Other Indications

Subsegments:

1) By Gene Therapy: Viral Vector-Based Gene Therapy, Non-Viral Gene Therapy, Plasmid DNA-Based Gene Therapy

2) By Gene-Modified Cell Therapy: CAR-T Cell Therapy, TCR-T Cell Therapy, NK Cell Therapy

3) By Cell Therapy: Stem Cell Therapy, Progenitor Cell Therapy, Immune Cell Therapy

Which Industry Trends Are Shaping the Future of the Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market?

Leading corporations in the cell and gene therapy contract development and manufacturing organization (CDMO) market are making concerted efforts to broaden their offerings with technological advancements like PluriMatrix. This is with the aim of boosting scalability, productivity, and the standard of cell-based goods production. The PluriMatrix system is specifically designed for high-volume production of cell-based items. Ensuring high yield and uniform quality, this technology enhances the 3D expansion of cells on a commercial scale through a validated, automated, and fully controlled process. For example, in January 2024, Pluri, a biotech company based in Israel, introduced PluriCDMO, a fresh business unit offering cell therapy manufacturing services under the CDMO model. The new unit encompasses a 47,000-square-foot facility for good manufacturing practice (GMP) cell therapy production. Pluri’s new division delivers comprehensive services, from early preclinical stages to late-stage clinical trials and eventual commercialization. This encompasses process and analytical development, scale-up, validation, logistics, automation, and regulatory-approved comparability studies, as elucidated in an official company announcement. With its advanced PluriMatrix technology, the company is able to provide sophisticated cell therapy manufacturing services.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/cell-and-gene-therapy-contract-development-and-manufacturing-organization-cdmo-global-market-report

Which Countries Are Leading the Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market?

North America was the largest region in the cell and gene therapy contract development and manufacturing organization (CDMO) market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cell and gene therapy contract development and manufacturing organization (CDMO) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15753

This Report Delivers Insight On:

1. How big is the cell and gene therapy contract development and manufacturing organization (cdmo) market, and how is it changing globally?

2. Who are the major companies in the cell and gene therapy contract development and manufacturing organization (cdmo) market, and how are they performing?

3. What are the key opportunities and risks in the cell and gene therapy contract development and manufacturing organization (cdmo) market right now?

4. Which products or customer segments are growing the most in the cell and gene therapy contract development and manufacturing organization (cdmo) market?

5. What factors are helping or slowing down the growth of the cell and gene therapy contract development and manufacturing organization (cdmo) market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Discover trends, market shifts, and competitive outlooks for the cell and gene therapy contract development and manufacturing organization (cdmo) industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research

What Is the Current and Projected Market Size of the Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market Through 2034?

The market size of the contract development and manufacturing organization (CDMO) for cell and gene therapy has noticeably expanded over the past few years. It is projected to rise from $5.41 billion in 2024 to $6.94 billion in 2025, presenting a compound annual growth rate (CAGR) of 28.2%. Factors like advancements in technology, regulatory environment favoring its growth, higher investment, a higher incidence of genetic disorders, and an upsurge in strategic collaborations have contributed to the growth during the historical period.

The market for contract development and manufacturing organizations (CDMO) in cell and gene therapy is anticipated to witness substantial expansion in the impending years. The market’s worth is predicted to soar to $18.54 billion in 2029, with a compound annual growth rate (CAGR) of 27.8%. This substantial growth in the forecasted period can be ascribed to numerous factors including the extension of therapeutic applications, developments in regulations, amplified investments, technological advancements, and international cooperation. In the forecast period, key trends to expect encompass an escalating demand for individualized therapies, development in automation and digitalization, broadening of manufacturing capabilities, emergence of innovative delivery systems, and an intensified emphasis on sustainability and ecological impact.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15753&type=smp

What External and Internal Drivers Are Contributing to the Growth of the Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market?

The escalating incidence of cancer is predicted to spur the expansion of the cell and gene therapy contract development and manufacturing organization (CDMO) market. Defined as a cluster of illnesses marked by uncontrolled proliferation and distribution of abnormal cells within the body, cancer’s growing incidence can be attributed to factors such as an aging demographic, lifestyle modifications, exposure to harmful environments, and more sophisticated detection techniques. CDMOs play an instrumental role in curtailing the incidence of cancer by creating and producing targeted, innovative treatments that amplify efficacy and improve patient results. Macmillan Cancer Support, a UK-based charity, projected in October 2022 that the number of individuals in the UK living with cancer is anticipated to surge from 3 million in 2022 to 3.5 million by 2025, 4 million by 2030, and ultimately reach 5.3 million by 2040. Thus, the escalating incidence of cancer propels expansion in the cell and gene therapy contract development and manufacturing organization (CDMO) market.

What Segment Types Define the Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market Structure?

The cell and gene therapy contract development and manufacturing organization (CDMO) market covered in this report is segmented –

1) By Product Type: Gene Therapy, Gene-Modified Cell Therapy, Cell Therapy

2) By Phase: Phase 1, Phase 2, Phase 3, Phase 4

3) By Indication: Oncology, Infectious Diseases, Neurological Disorders, Rare Diseases, Other Indications

Subsegments:

1) By Gene Therapy: Viral Vector-Based Gene Therapy, Non-Viral Gene Therapy, Plasmid DNA-Based Gene Therapy

2) By Gene-Modified Cell Therapy: CAR-T Cell Therapy, TCR-T Cell Therapy, NK Cell Therapy

3) By Cell Therapy: Stem Cell Therapy, Progenitor Cell Therapy, Immune Cell Therapy

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=15753&type=smp

Which Geographic Areas Hold the Strongest Growth Potential in the Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market?

North America was the largest region in the cell and gene therapy contract development and manufacturing organization (CDMO) market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cell and gene therapy contract development and manufacturing organization (CDMO) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Which Cutting-Edge Market Trends Are Expected to Drive the Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market’s Growth?

Prominent corporations in the cell and gene therapy contract development and manufacturing organization (CDMO) market are aiming to enlarge their offerings using sophisticated solutions like PluriMatrix technology, to improve the scalability, productivity, and caliber of cell-based product development. PluriMatrix technology is a proprietary system designed for mass production of cell-based items. This progressive technology enables the 3D expansion of cells on a commercial level, ensuring high output and reliability via an automated, fully managed, and verified procedure. For example, Pluri, a biotech firm based in Israel, unveiled PluriCDMO, a new business sector that offers cell therapy production services as a CDMO, in January 2024. The new sector includes a good manufacturing practice (GMP) cell therapy manufacturing facility spanning 47,000 square feet. Pluri’s newly formed division provides comprehensive services right from the early preclinical phases to late-stage clinical tests and commercialization, offering process and analytical development, scale-up, validation, logistics, automation, and regulatory-approved comparability studies, according to a company announcement. The company’s state-of-the-art PluriMatrix technology is utilized in this division to provide advanced cell therapy manufacturing services.

View the full report here:

https://www.thebusinessresearchcompany.com/report/cell-and-gene-therapy-contract-development-and-manufacturing-organization-cdmo-global-market-report

What Is the Definition of the Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market?

A cell and gene therapy contract development and manufacturing organization (CDMO) is a specialized company that provides services to support the development, manufacturing, and commercialization of cell-based and gene therapy products. These organizations offer services tailored to the unique needs of companies developing advanced therapies, including biopharmaceutical companies, academic institutions, and government agencies. Cell and gene therapy CDMOs play a critical role in accelerating the development and commercialization of advanced therapy products by offering specialized expertise, infrastructure, and services to support their clients’ needs from early-stage development through commercialization.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15753

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

How has the cell and gene therapy contract development and manufacturing organization (cdmo) market grown over the years?

The cell and gene therapy contract development and manufacturing organization (CDMO) market has seen exponential growth in recent years. It will increase from $5.41 billion in 2024 to $6.94 billion in 2025, reflecting a compound annual growth rate (CAGR) of 28.2%. The historical growth is attributed to technological advancements, favorable regulatory frameworks, greater investment in the sector, the high prevalence of genetic disorders, and a rising number of strategic partnerships.

What Is the forecasted market size and growth rate for the cell and gene therapy contract development and manufacturing organization (cdmo) market?

The cell and gene therapy contract development and manufacturing organization (CDMO) market is forecast to grow to $18.54 billion by 2029 at a CAGR of 27.8%. This growth is driven by expanded therapeutic applications, regulatory evolution, technological innovations, and global collaboration. Trends include increased demand for personalized therapies, automation and digitalization, manufacturing capacity expansion, novel delivery systems, and sustainability.

Get your cell and gene therapy contract development and manufacturing organization (cdmo) market report here!

https://www.thebusinessresearchcompany.com/report/cell-and-gene-therapy-contract-development-and-manufacturing-organization-cdmo-global-market-report

What are the major factors driving growth in the cell and gene therapy contract development and manufacturing organization (cdmo) market?

The increasing prevalence of cancer is set to drive the growth of the cell and gene therapy contract development and manufacturing organization (CDMO) market. The rise in cancer cases is linked to aging populations, lifestyle changes, and better detection methods. CDMOs play a role in developing targeted therapies for cancer that improve treatment efficacy. For instance, in October 2022, Macmillan Cancer Support projected that the number of people living with cancer in the UK would rise from 3 million in 2022 to 5.3 million by 2040. The increasing cancer burden is driving the CDMO market.

What key areas define the segmentation of the global cell and gene therapy contract development and manufacturing organization (cdmo) Market?

The cell and gene therapy contract development and manufacturing organization (CDMO) market covered in this report is segmented –

1) By Product Type: Gene Therapy, Gene-Modified Cell Therapy, Cell Therapy

2) By Phase: Phase 1, Phase 2, Phase 3, Phase 4

3) By Indication: Oncology, Infectious Diseases, Neurological Disorders, Rare Diseases, Other Indications

Subsegments:

1) By Gene Therapy: Viral Vector-Based Gene Therapy, Non-Viral Gene Therapy, Plasmid DNA-Based Gene Therapy

2) By Gene-Modified Cell Therapy: CAR-T Cell Therapy, TCR-T Cell Therapy, NK Cell Therapy

3) By Cell Therapy: Stem Cell Therapy, Progenitor Cell Therapy, Immune Cell Therapy

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15753&type=smp

What are the top market players propelling the growth of the cell and gene therapy contract development and manufacturing organization (cdmo) industry?

Major companies operating in the cell and gene therapy contract development and manufacturing organization (CDMO) market are Pfizer Inc., Merck & Co. Inc., Thermo Fisher Scientific Inc., Novartis AG, FUJIFILM Diosynth Biotechnologies, AGC Biologics, Ajinomoto Co Inc., Lonza Group, Catalent Inc., Charles River Laboratories International Inc., Sartorius Stedim Biotech, Samsung Biologics Co Ltd., WuXi Biologics, Recipharm AB, Almac Group Ltd., KBI Biopharma, Rentschler Biopharma, Bio Elpida, Oxford BioMedica Plc, Avid Bioservices Inc., Cell and Gene Therapy Catapult, VGXI Inc., Genezen Laboratories Inc., Pluri Inc., OmniaBio Inc.

What are the key trends shaping the future of the cell and gene therapy contract development and manufacturing organization (cdmo) market?

Companies in the cell and gene therapy contract development and manufacturing organization (CDMO) market are expanding their portfolios with technologies like PluriMatrix to boost scalability and manufacturing efficiency. PluriMatrix is a proprietary technology for large-scale cell-based product production. For instance, in January 2024, Israel-based Pluri introduced PluriCDMO, a new division offering cell therapy manufacturing services. The division includes a GMP-certified facility and provides end-to-end services, including preclinical to commercial-scale production, process validation, and regulatory support.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15753

What regions are dominating the cell and gene therapy contract development and manufacturing organization (cdmo) market growth?

North America was the largest region in the cell and gene therapy contract development and manufacturing organization (CDMO) market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cell and gene therapy contract development and manufacturing organization (CDMO) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Browse Through More Similar Reports By The Business Research Company:

Cellular or Mobile Telephone Services Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/cellular-or-mobile-telephone-services-global-market-report

Cell And Gene Therapy Supply Chain/Logistics Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/cell-and-gene-therapy-supply-chain-or-logistics-global-market-report

Cell and Gene Therapy Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/cell-and-genes-therapy-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: